Sutro Biopharma Inc (nasdaq:STRO) Share Price

Company Profile

Business description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Contact
111 Oyster Point Boulevard
South San FranciscoCA94080
USA
T: +1 650 881-6500
https://www.sutrobio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
269

Recommended

We raise our risk and uncertainty rating to reflect the impact of the ruling.

Esther Holloway | 13 July 2025

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Sarah Hansen | 10 July 2025

Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.

Shaun Ler | 10 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,815.30	5.00	-0.06%
CAC 40	7,808.17	21.12	-0.27%
DAX 40	24,160.64	94.67	-0.39%
Dow JONES (US)	44,392.41	20.90	0.05%
FTSE 100	8,998.06	56.94	0.64%
HKSE	24,203.32	63.75	0.26%
NASDAQ	20,638.02	52.49	0.26%
Nikkei 225	39,459.62	110.06	-0.28%
NZX 50 Index	12,678.69	7.99	-0.06%
S&P 500	6,264.36	4.61	0.07%
S&P/ASX 200	8,570.40	9.70	-0.11%
SSE Composite Index	3,519.65	9.47	0.27%